Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Sells $867,350.00 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) CEO Saurabh Saha sold 55,000 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $15.77, for a total transaction of $867,350.00. Following the completion of the transaction, the chief executive officer now owns 429,398 shares of the company’s stock, valued at approximately $6,771,606.46. This represents a 11.35 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Saurabh Saha also recently made the following trade(s):

• On Friday, December 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $17.44, for a total transaction of $959,200.00.
• On Friday, December 6th, Saurabh Saha sold 87,496 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.46, for a total value of $1,615,176.16.
• On Monday, November 25th, Saurabh Saha sold 299 shares of Centessa Pharmaceuticals stock. The stock was sold at an average price of $18.23, for a total value of $5,450.77.
• On Wednesday, November 20th, Saurabh Saha sold 55,000 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $16.89, for a total value of $928,950.00.
• On Friday, November 22nd, Saurabh Saha sold 1,671 shares of Centessa Pharmaceuticals stock. The shares were sold at an average price of $18.24, for a total value of $30,479.04.

Centessa Pharmaceuticals Trading Up 1.1 %

CNTA opened at $16.46 on Friday. Centessa Pharmaceuticals plc has a 1-year low of $7.38 and a 1-year high of $18.97. The firm has a 50-day moving average price of $16.79 and a two-hundred day moving average price of $14.85. The stock has a market capitalization of $2.17 billion, a PE ratio of -10.76 and a beta of 1.53. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.05. As a group, equities analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages recently issued reports on CNTA. Guggenheim increased their target price on shares of Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating for the company. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals has an average rating of “Buy” and a consensus target price of $25.83.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC raised its stake in shares of Centessa Pharmaceuticals by 29.1% during the fourth quarter. GAMMA Investing LLC now owns 3,837 shares of the company’s stock worth $64,000 after buying an additional 865 shares during the last quarter. Atria Investments Inc lifted its holdings in Centessa Pharmaceuticals by 7.0% in the third quarter. Atria Investments Inc now owns 17,134 shares of the company’s stock valued at $274,000 after buying an additional 1,116 shares during the period. Quarry LP boosted its stake in Centessa Pharmaceuticals by 47.8% in the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. grew its holdings in Centessa Pharmaceuticals by 39.1% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company’s stock worth $317,000 after acquiring an additional 5,316 shares during the period. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.